Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6572-6575

  Zhao, Zhong ^a   Araldi, Gian Luca ^a   Xiao, Yufang ^a   Reddy, Adulla P ^a   Liao, Yihua ^a   Karra, Srinivasa ^a   Brugger, Nadia ^a   Fischer, David ^a   Palmer, Elizabeth ^a  

^a EMD SERONO INC   (United States)

Author keywords

Agonist; EP2; EP4; Prostaglandin

Indexed keywords

PROSTAGLANDIN E2; PROSTAGLANDIN E4; PROSTAGLANDIN RECEPTOR; PYRAZOLE DERIVATIVE; PYRAZOLIDIN 3 ONE DERIVATIVE; PYRAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MICHAEL ADDITION; NONHUMAN; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; DINOPROSTONE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MICE; PYRAZOLES; RATS; RECEPTORS, PROSTAGLANDIN E;

EID: 35648935414     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.074     Document Type: Article

References (25)

1. Funk C.D. Science 294 (2001) 1871
2. Narumiya S., Sugimoto Y., and Ushikubi F. Pharm. Rev. 79 (1999) 1193
3. Regan J. Life. Sciences 74 (2003) 143
4. Kobayashi T., and Narumiya S. Prostaglandin other Lipid Mediat. 68-69 (2002) 557
5. Sugimoto Y., Narumiya S., and Ichikawa A. Prog. Lipid Res. 39 (2000) 289
6. Boie Y., Stocco R., Sawyer N., Slipetz D., Ungrin M., Neuschafer-Rube F., Puschel G., Metters K., and Abranovitz M. Eur. J. Pharm. 340 (1997) 227
7. Yamamoto S. Comp. Nat. Prod. Chem. 1 (1999) 255
8. Goto M.P., and Goldman A.S. Handbook Exp. Pharmacol. 124 (1997) 433 Drug Toxicity in Embryonic Development I
9. Collins P.W., and Djuric S.W. Chem. Rev. 93 (1993) 1533
10. Cameron, K. O.; Lefker, B. A.; Crawford, D. T.; DaSilva-Jardine, P.; DeNinno, S. L.; Gilbert, S.; Grasser, W. A.; Ke, H. Z.; Lu, B.; Owen, T. A.; Paralkar, V. M.; Thompson, D. D.; Tjoa, C. M.; Zamistoski, M. P.; Abstracts of Papers, 224th National Meeting of the American Chemical Society, Boston, MA 2002.
11. Billot X., Chateauneuf A., Chauret N., Denis D., Greig G., Mathieu M.-C., Metters K.M., Slipetz D.M., and Young R.N. Bioorg. Med.Chem. Lett. 13 (2003) 1129
12. th National Meeting of the American Chemical Society, Boston, MA, 2004.
13. Xiao Y., Araldi G.L., Zhao Z., Brugger N., Karra S., Fischer D., and Palmer E. Bioorg. Med. Chem. Lett. 17 (2007) 4323
14. Tani K., Naganwa A., Ishida A., Egashira H., Sagawa K., Harada H., Ogawa M., Maruyama T., Ohuchida S., Nakai H., Kondo K., and Toda M. Bioorg. Med. Chem. Lett. 11 (2001) 2025
15. Elworthy T.R., Brill E.R., Chiou F.C., Harris J.R., Hendricks R.T., Huang J., Kim W., Lach L.K., Miradegan T., Yee C., and Walker K.A.M. J. Med. Chem. 47 (2004) 6124
16. Maruyama, T.; kambe, T.; Maruyama, T.; Yoshida, H. ; Nishiura, A. WO 2003/009872 A1.
17. El-Masry A. Pak. J. Sci. Ind. Res. 45 (2002) 69
18. Kozlecki T., Samyn C., Alder K., and Green P.G. J. Chem. Soc. Perkin Trans. 2 2 (2001) 243
19. Kim M., Lee H., Han K., and Kay K. Synth. Commun. 23 (2003) 4013
20. Ndungu J.M., Larson K., and Sarpong R. Org. Lett. 7 (2005) 5845
21. Rossiter B.E., Verhoeven T.R., and Sharpless K.B. Tetrahedron Lett. (1979) 4733
22. Wipf P., and Lim S.J. Am. Chem. Soc. 117 (1995) 558
23. Gardiner P.J. Br. J. Pharmac. 87 (1986) 45
24. -6 cm/s. Rat plasma protein binding of compound 10f (C = 10 mM, 2 h) was 61% unbound. After 1 h, live microsomes degradation was 7% in rat and 0% in human, respectively. The solubility of compound 10f was measured to be 0.89 mg/mL in 2% DMSO in HBSS or 0.84 mg/mL in 2%DMSO in saline. The result at intravenous administration is not disclosed here.
25. We tested compounds in ovulation induction in two routes: intravenous, subcutaneous. 2% DMSO + saline was used to be vehicle control and FSH was a positive control.